Carlsbad, California, United States, October 13, 2026
Rapalogix Health, Inc. has announced the publication of peer-reviewed clinical findings evaluating Re-Q Longevity Face Serum, a skincare formulation powered by its proprietary longevity molecule RLX-201. Published in the Journal of Cosmetic Dermatology, the study reported improvements in skin firmness, elasticity, texture and other visible signs of facial photoaging following 12 weeks of twice-daily application. The randomized, double-blind, vehicle-controlled study assessed the formulation in women aged 35 to 65 with moderate-to-severe facial photoaging. The findings also included improvements in objectively measured skin biomechanics and laboratory evidence of activity against TORC1, a cellular signaling pathway associated with aging-related processes. Rapalogix said the results support its science-driven approach to skincare, which focuses on biological mechanisms involved in maintaining skin structure and function. Although the findings are promising, the study was relatively small and lasted 12 weeks, meaning further research will be needed to establish the durability and broader applicability of the observed effects.
Clinical Study Shows Improvements in Skin Firmness and Elasticity
The clinical study enrolled 47 women aged 35–65 years, representing Fitzpatrick skin types I through VI. Participants were randomly assigned to receive either the RLX-201-containing formulation or a matching vehicle formulation, with 31 participants in the active-treatment group and 16 in the control group. Both formulations were applied twice daily over a 12-week period, with assessments conducted at baseline and Weeks 2, 4, 8 and 12. According to the published results, the RLX-201 formulation demonstrated a statistically significant advantage over the vehicle in improving skin firmness as early as Week 2, with continued improvement through Week 12. At Week 12, investigator assessments showed improvements of 21% from baseline in skin firmness and cheek wrinkles, while sagging, orbital elasticity and skin tone improved by 14%. Skin texture improved by 40%, radiance by 39% and luminosity by 38% from baseline. These percentages describe changes from the treatment group’s baseline assessments and should not be interpreted as equivalent placebo-adjusted treatment effects. The researchers also reported that the active formulation outperformed the vehicle in measured skin viscoelastic properties throughout the study.
RLX-201 Targets the TORC1 Cellular Signaling Pathway
The formulation’s principal investigational ingredient, RLX-201, is designed to selectively modulate the mechanistic target of rapamycin complex 1 (TORC1) signaling pathway. TORC1 helps regulate cellular growth, metabolism and protein synthesis in response to nutrients and other signals. Researchers studying skin aging are interested in how changes in this pathway may influence fibroblast activity and the extracellular matrix, which includes structural proteins such as collagen and elastin. These proteins contribute to skin strength, flexibility and resilience. To investigate the biological mechanism, researchers used three-dimensional, full-thickness human skin models from three independent donors. They measured phosphorylated ribosomal protein S6 (pRPS6), a marker used to assess TORC1 pathway activity. The RLX-201 formulation reduced pRPS6 by an average of 91.7% across the three skin-model donors, indicating substantial pathway suppression under the experimental conditions. Exploratory biopsy analyses were also associated with increases in dermal collagen and elastin. These mechanistic findings provide scientific context for the clinical observations, but laboratory pathway changes do not independently establish long-term benefits or prove that the same biological effects occur to the same extent in all users.
Advertisement
Patient Feedback and Safety Findings Support Further Research
The study also collected participant-reported assessments of skin appearance and product experience. Eighty-six percent of participants reported improvements in hydration, radiance and skin texture, and the same proportion said they would recommend the product. The researchers reported that both the active formulation and the vehicle were well tolerated, with no adverse events reported during the study. While these findings are encouraging, the absence of reported adverse events in a small, short-term study does not rule out uncommon reactions or risks associated with longer use. The results were published in the Journal of Cosmetic Dermatology under the title “A Novel TORC1 Inhibitor, RLX-201, Improves Skin Health, Biomechanics, and Extracellular Matrix Integrity in a Double-Blind Clinical Study.” The research was conducted at Dermatology Consulting Services in High Point, North Carolina, under principal investigator Zoe D. Draelos, MD. Rapalogix is continuing research into RLX-201 and related skin-health programs, with the aim of expanding its professional skincare portfolio. Future studies could help clarify the formulation’s long-term performance, reproducibility and suitability for broader consumer populations.
The publication marks a research milestone for Rapalogix Health and its Re-Q skincare platform, combining controlled clinical assessments with laboratory investigation of a skin-aging pathway. The reported improvements in firmness, elasticity and skin quality warrant further evaluation, while larger and longer studies will be important to determine how consistently these benefits can be reproduced.
Source: Rapalogix Health press release
